Interesting possibility. So J&J fronts the money, but takes it off their books? The gal heading up the Med Device business was pretty emphatic that they would be out of Diabetic Care by end of 2018 at the May update meeting. Would J&J be making the investment in hopes of bringing it back into their business if this management team can turn it around? Outside of that, I see no benefit for the overall corporation in making this offer. Maybe I'm missing something, but doesn't seem like a good deal for J&J.

We only have two weeks to wait to see if it materializes or not. If I'm Platinum and realize there is a competing bid outside of my offer, I'd say no to the extension, or the hair cutting begins and the offer goes down $100M per month they delay.

I'm sure we'll see some other potential theories coming out shortly...